Giotrif.com
Top giot sites |
Top rif sites |
- Title
- GIOTRIF® (afatinib) | 1st Line Treatment of EGFR M+ mNSCLC
- Meta Description
- GIOTRIF® is indicated for 1st line treatment of patients with metastatic NSCLC whose tumors have common epidermal growth factor receptor (EGFR) mutations.
- Meta Keywords
- boehringer-ingelheim, boehringer-ingleheim, böhringer-ingelheim, boehringer, böhringer, ingelheim, ingleheim